Adaptimmune Therapeutics (ADAP) News Today → This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad) Free ADAP Stock Alerts $1.10 -0.01 (-0.90%) (As of 05:18 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 1:22 PM | msn.comEuropean Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday TradingMay 19 at 2:38 AM | americanbankingnews.comMizuho Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $3.00May 18 at 2:43 AM | americanbankingnews.comAdaptimmune Therapeutics plc Forecasted to Post Q2 2024 Earnings of ($0.17) Per Share (NASDAQ:ADAP)May 18 at 1:01 AM | americanbankingnews.comStockNews.com Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) to SellMay 17 at 8:28 AM | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $3.00 at MizuhoMizuho cut their target price on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday.May 17 at 8:25 AM | marketbeat.comLeerink Partnrs Weighs in on Adaptimmune Therapeutics plc's Q2 2024 Earnings (NASDAQ:ADAP)Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q2 2024 earnings per share estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. Leerink Partnrs analyst J. ChangMay 16, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comAdaptimmune Q1 2024 Earnings PreviewMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Fate Therapeutics (FATE) and Instil Bio (TIL)May 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)April 29, 2024 | finance.yahoo.comGlobal CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & PhaseApril 26, 2024 | seekingalpha.comAdaptimmune: Huge Opportunity Amid Their Setback With GenentechApril 26, 2024 | bizjournals.comGenentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to matchApril 24, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 5.3% Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 5.3%April 24, 2024 | money.usnews.comAdaptimmune Therapeutics Plc - ADRApril 24, 2024 | finance.yahoo.comGarry Menzel joins GHO Capital as Operating PartnerApril 19, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week DownApril 19, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Up 12.4%Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 12.4%April 16, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 4.8% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 4.8%April 16, 2024 | markets.businessinsider.comMaintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration TerminationApril 12, 2024 | bizjournals.comAdaptimmune shares drop as Genentech terminates potential $3B dealApril 12, 2024 | msn.comAdaptimmune falls as Roche strategic collaboration endsApril 11, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Up 3.9%Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 3.9%April 11, 2024 | marketbeat.comBaillie Gifford & Co. Sells 1,235,269 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)Baillie Gifford & Co. lowered its holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 7.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,912,140 shares of the biotechnologyApril 1, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 3.8% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 3.8%April 1, 2024 | marketbeat.comShort Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Expands By 11.1%Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 3,110,000 shares, a growth of 11.1% from the February 29th total of 2,800,000 shares. Based on an average daily volume of 1,850,000 shares, the days-to-cover ratio is currently 1.7 days.March 26, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 2.1%Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 2.1%March 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)March 22, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading 4.5% Higher Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 4.5%March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)March 21, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.33Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.33March 18, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 6.1% Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 6.1%March 15, 2024 | benzinga.comPeter W. Sonsini's Net WorthMarch 15, 2024 | finance.yahoo.comADAP Sep 2024 2.500 putMarch 14, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.59Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Down to $1.59March 13, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday TradingMarch 13, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.49Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.49March 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)March 11, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 4%Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 4%March 8, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Sees Unusually-High Trading VolumeAdaptimmune Therapeutics (NASDAQ:ADAP) Sees Unusually-High Trading VolumeMarch 8, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Strong Clinical Results and Commercial StrategyMarch 8, 2024 | finance.yahoo.comAdaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 8, 2024 | marketbeat.comBrokers Issue Forecasts for Adaptimmune Therapeutics plc's Q1 2024 Earnings (NASDAQ:ADAP)Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Adaptimmune Therapeutics in a research note issued to investors on Wednesday, March 6th. Leerink Partnrs analyst J. Chang anticiMarch 7, 2024 | benzinga.comAdaptimmune Therapeutics Earnings PreviewMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial ResultsMarch 7, 2024 | finance.yahoo.comAdaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial ResultsMarch 7, 2024 | marketbeat.comAdaptimmune Therapeutics (NASDAQ:ADAP) Hits New 12-Month High at $1.85Adaptimmune Therapeutics (NASDAQ:ADAP) Sets New 12-Month High at $1.85March 7, 2024 | finance.yahoo.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Boost your retirement with these AI payouts (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. ADAP Media Mentions By Week ADAP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAP News Sentiment▼-0.360.42▲Average Medical News Sentiment ADAP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAP Articles This Week▼142▲ADAP Articles Average Week Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: STRO News CADL News PSTX News GLUE News FENC News CHRS News IVVD News AGEN News MGX News CMPX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAP) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 Media"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Former CIA advisor: Dark side of AI now startingParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
